EOSPA provides fractional product development and CMC leadership to emerging and growth-stage biotech companies.
We operate at the intersection of strategy, execution, and decision-making under uncertainty- where programs often succeed or fail.
From IND-enabling through clinical execution, we partner with teams to bring structure to complexity, align cross-functional efforts, and ensure programs move forward with clarity and discipline.
Our focus is simple: helping programs not just look viable on paper, but hold up in real-world execution- avoiding costly downstream rework and delays.
Based in the Washington, DC area, EOSPA supports clients across the U.S. and globally.
